The INHBE Knockout AGS Polyclonal Cells are a CRISPR/Cas9-edited heterogeneous population of AGS gastric adenocarcinoma cells engineered for disruption of the INHBE gene. This polyclonal knockout pool circumvents clonal biases and provides a genetically varied loss-of-function model for interrogating INHBE-dependent processes. By ablating expression of the inhibin beta E subunit, the product prevents formation of activin E homodimers and eliminates downstream signaling, offering a potent tool for functional studies.
The AGS host cell line originates from a primary gastric adenocarcinoma of a 54-year-old female and serves as a well-established epithelial model. This adherent line is widely adopted in gastric cancer research and Helicobacter pylori infection studies, owing to its reproducible growth and signaling characteristics. The INHBE knockout thus permits investigation of the gene??s role specifically within the gastric epithelial context, where potential links between metabolic signaling and cancer biology can be explored.
INHBE encodes a TGF-?? superfamily ligand that assembles into the activin E homodimer. Activin E binds type II receptors ACVR2A and ACVR2B, leading to recruitment and phosphorylation of ACVR1B (ALK-4). This triggers SMAD2 and SMAD3 phosphorylation, partnering with SMAD4 to regulate transcription of genes involved in energy homeostasis, adiposity, and body fat distribution. Upstream regulators include insulin, glucocorticoids, HNF4A, and CEBPA, while downstream targets encompass UCP1 and PPARGC1A. The pathway is modulated by antagonists such as follistatin.
In the AGS gastric adenocarcinoma line, disruption of INHBE?Cactivin E signaling allows dissection of its contribution to epithelial cell behavior. Given the interplay between metabolic dysregulation and gastric malignancies, this model enables examination of crosstalk between TGF-??/activin pathways and cancer cell phenotypes, including proliferation, migration, and invasion. It also provides a platform to study how activin E loss affects cellular metabolic responses within the gastric lineage, potentially yielding insights into obesity-related gastric pathologies.
Typical applications include western blotting for INHBE and phospho-SMAD2/3, RT-qPCR for transcript verification, Sanger sequencing of the edited locus, SMAD-responsive luciferase reporter assays, and phenotypic analyses such as proliferation and Transwell migration/invasion tests. RNA-seq can be employed for comprehensive transcriptomic profiling. The model supports functional genomics, metabolic disease research, and drug target validation. For further details, please contact Ascent Research.
